These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
185 related articles for article (PubMed ID: 37917623)
1. Intranasal challenge with B. pertussis leads to more severe disease manifestations in mice than aerosol challenge. Weaver KL; Bitzer GJ; Wolf MA; Pyles GM; DeJong MA; Dublin SR; Huckaby AB; Gutierrez MP; Hall JM; Wong TY; Warden M; Petty JE; Witt WT; Cunningham C; Sen-Kilic E; Damron FH; Barbier M PLoS One; 2023; 18(11):e0286925. PubMed ID: 37917623 [TBL] [Abstract][Full Text] [Related]
2. Protocol for aerosolization challenge of mice with Bordetella pertussis. Bitzer G; Weaver K; Barbier M; Damron FH STAR Protoc; 2023 Mar; 4(1):101979. PubMed ID: 36598856 [TBL] [Abstract][Full Text] [Related]
3. Intranasal immunization with outer membrane vesicle pertussis vaccine confers broad protection through mucosal IgA and Th17 responses. Raeven RHM; Rockx-Brouwer D; Kanojia G; van der Maas L; Bindels THE; Ten Have R; van Riet E; Metz B; Kersten GFA Sci Rep; 2020 Apr; 10(1):7396. PubMed ID: 32355188 [TBL] [Abstract][Full Text] [Related]
4. Bordetella pertussis filamentous hemagglutinin: evaluation as a protective antigen and colonization factor in a mouse respiratory infection model. Kimura A; Mountzouros KT; Relman DA; Falkow S; Cowell JL Infect Immun; 1990 Jan; 58(1):7-16. PubMed ID: 2294058 [TBL] [Abstract][Full Text] [Related]
5. Protection of mice against respiratory Bordetella pertussis infection by intranasal immunization with P.69 and FHA. Roberts M; Cropley I; Chatfield S; Dougan G Vaccine; 1993; 11(8):866-72. PubMed ID: 8356847 [TBL] [Abstract][Full Text] [Related]
6. Intranasal murine model of Bordetella pertussis infection. I. Prediction of protection in human infants by acellular vaccines. Guiso N; Capiau C; Carletti G; Poolman J; Hauser P Vaccine; 1999 May; 17(19):2366-76. PubMed ID: 10392618 [TBL] [Abstract][Full Text] [Related]
7. Construction and preliminary immunobiological characterization of a novel, non-reverting, intranasal live attenuated whooping cough vaccine candidate. Cornford-Nairns R; Daggard G; Mukkur T J Microbiol Biotechnol; 2012 Jun; 22(6):856-65. PubMed ID: 22573165 [TBL] [Abstract][Full Text] [Related]
8. Quantitative priming with inactivated pertussis toxoid vaccine in the aerosol challenge model. Bruss JB; Siber GR Infect Immun; 2002 Aug; 70(8):4600-8. PubMed ID: 12117973 [TBL] [Abstract][Full Text] [Related]
10. Intranasal Immunization with Acellular Pertussis Vaccines Results in Long-Term Immunity to Bordetella pertussis in Mice. Wolf MA; Boehm DT; DeJong MA; Wong TY; Sen-Kilic E; Hall JM; Blackwood CB; Weaver KL; Kelly CO; Kisamore CA; Bitzer GJ; Bevere JR; Barbier M; Damron FH Infect Immun; 2021 Feb; 89(3):. PubMed ID: 33318136 [No Abstract] [Full Text] [Related]
11. Immune responses and protection against Bordetella pertussis infection after intranasal immunization of mice with filamentous haemagglutinin in solution or incorporated in biodegradable microparticles. Cahill ES; O'Hagan DT; Illum L; Barnard A; Mills KH; Redhead K Vaccine; 1995 Apr; 13(5):455-62. PubMed ID: 7639014 [TBL] [Abstract][Full Text] [Related]
12. Lung pathology and immediate hypersensitivity in a mouse model after vaccination with pertussis vaccines and challenge with Bordetella pertussis. Vandebriel RJ; Gremmer ER; Vermeulen JP; Hellwig SM; Dormans JA; Roholl PJ; Mooi FR Vaccine; 2007 Mar; 25(12):2346-60. PubMed ID: 17224216 [TBL] [Abstract][Full Text] [Related]
13. Development of vaccines against pertussis caused by Bordetella holmesii using a mouse intranasal challenge model. Saito M; Odanaka K; Otsuka N; Kamachi K; Watanabe M Microbiol Immunol; 2016 Sep; 60(9):599-608. PubMed ID: 27515393 [TBL] [Abstract][Full Text] [Related]
14. Protective effects of vaccines against Bordetella parapertussis in a mouse intranasal challenge model. Komatsu E; Yamaguchi F; Eguchi M; Watanabe M Vaccine; 2010 Jun; 28(27):4362-8. PubMed ID: 20438876 [TBL] [Abstract][Full Text] [Related]
15. Sustained protective immunity against Bordetella pertussis nasal colonization by intranasal immunization with a vaccine-adjuvant combination that induces IL-17-secreting T Allen AC; Wilk MM; Misiak A; Borkner L; Murphy D; Mills KHG Mucosal Immunol; 2018 Nov; 11(6):1763-1776. PubMed ID: 30127384 [TBL] [Abstract][Full Text] [Related]
16. Mice are protected against Bordetella pertussis infection by intra-nasal immunization with filamentous haemagglutinin. Cahill ES; O'Hagan DT; Illum L; Redhead K FEMS Microbiol Lett; 1993 Mar; 107(2-3):211-6. PubMed ID: 8472903 [TBL] [Abstract][Full Text] [Related]
17. Intranasal Immunization With a c-di-GMP-Adjuvanted Acellular Pertussis Vaccine Provides Superior Immunity Against Jiang W; Wang X; Su Y; Cai L; Li J; Liang J; Gu Q; Sun M; Shi L Front Immunol; 2022; 13():878832. PubMed ID: 35493458 [TBL] [Abstract][Full Text] [Related]
18. Mutants of Escherichia coli heat-labile toxin act as effective mucosal adjuvants for nasal delivery of an acellular pertussis vaccine: differential effects of the nontoxic AB complex and enzyme activity on Th1 and Th2 cells. Ryan EJ; McNeela E; Murphy GA; Stewart H; O'hagan D; Pizza M; Rappuoli R; Mills KH Infect Immun; 1999 Dec; 67(12):6270-80. PubMed ID: 10569737 [TBL] [Abstract][Full Text] [Related]
19. Heterologous prime-boost immunization with live attenuated B. pertussis BPZE1 followed by acellular pertussis vaccine in mice. Feunou PF; Kammoun H; Debrie AS; Locht C Vaccine; 2014 Jul; 32(34):4281-8. PubMed ID: 24950361 [TBL] [Abstract][Full Text] [Related]
20. Adjuvanticity and protective immunity elicited by Bordetella pertussis antigens encapsulated in poly(DL-lactide-co-glycolide) microspheres. Shahin R; Leef M; Eldridge J; Hudson M; Gilley R Infect Immun; 1995 Apr; 63(4):1195-200. PubMed ID: 7890372 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]